Visitación López-Miranda

Dr. Visitación López-Miranda

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Pharmacological Reports
Verified
Journal Article
Closed access
Jose UrangaJose Uranga
Jose Uranga
VLVisitación López-Miranda
Visitación López-Miranda
FLFelipe Lombó
Felipe Lombó
Raquel AbaloRaquel Abalo
Raquel Abalo

17 March 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MGMarta Garcés-Rimón
Marta Garcés-Rimón
CGC. González
C. González
Jose UrangaJose Uranga
Jose Uranga
VLVisitación López-Miranda
Visitación López-Miranda
RLR. López-Fandiño
R. López-Fandiño
Marta MiguelMarta Miguel
Marta Miguel
The aim of this work was to evaluate the effect of the administration of egg white hydrolysates on obesity-related disorders, with a focus on lipid metabolism, inflammation and oxidative stress, in Zucker fatty rats. Obese Zucker rats received water, pepsin egg white hydrolysate (750 mg/kg/day) or Rhizopus aminopeptidase egg white hydrolysate (750 mg/kg/day) for 12 weeks. Lean Zucker rats received water. Body weight, solid and liquid intakes were weekly measured. At the end of the study, urine, faeces, different organs and blood samples were collected. The consumption of egg white hydrolysed with pepsin significantly decreased the epididymal adipose tissue, improved hepatic steatosis, and lowered plasmatic concentration of free fatty acids in the obese animals. It also decreased plasma levels of tumor necrosis factor-alpha and reduced oxidative stress. Pepsin egg white hydrolysate could be used as a tool to improve obesity-related complications.

25 January 2011 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
CGCristina González
Cristina González
EHEsperanza Herradón
Esperanza Herradón
Raquel AbaloRaquel Abalo
Raquel Abalo
GVGema Vera
Gema Vera
BPBeatriz G. Pérez‐Nievas
Beatriz G. Pérez‐Nievas
VLVisitación López-Miranda
Visitación López-Miranda

1 November 2007 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
EHE Herradón
E Herradón
MMM I Martín
M I Martín
VLVisitación López-Miranda
Visitación López-Miranda

8 May 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
EHEsperanza Herradón
Esperanza Herradón
CGCristina González
Cristina González
Jose UrangaJose Uranga
Jose Uranga
Raquel AbaloRaquel Abalo
Raquel Abalo
MMMa I. Martín
Ma I. Martín
VLVisitación López-Miranda
Visitación López-Miranda
In the last years, many clinical studies have revealed that some cisplatin-treated cancer survivors have a significantly increased risk of cardiovascular events, being cisplatin-induced cardiovascular toxicity an increasing concern. The aim of the present work was to evaluate the cardiovascular alterations induced by different chronic cisplatin treatments, and to identify some of the mechanisms involved. Direct blood pressure, basal cardiac (left ventricle and coronary arteries) and vascular (aortic and mesenteric) functions were evaluated in chronic (5 weeks) saline- or cisplatin-treated male Wistar rats. Three different doses of cisplatin were tested (1, 2 and 3 mg/kg/week). Alterations in cardiac and vascular tissues were also investigated by immunohistochemistry, Western Blot and or quantitative RT-PCR analysis. Cisplatin treatment provoked a significant modification of arterial blood pressure, heart rate and basal cardiac function at the maximum dose tested. However, vascular endothelial dysfunction occurred at lower doses. The expression of collagen fibers and conexin-43 were increased in cardiac tissue in cisplatin-treated rats with doses of 2 and 3 mg/kg/week. The expression of endothelial nitric oxide synthase was also modified in cardiac and vascular tissues after cisplatin treatment. In conclusion, chronic cisplatin treatment provokes cardiac and vascular toxicity in a dose-dependent manner. Besides, vascular endothelial dysfunction occurs at lower doses than cardiac and systemic cardiovascular toxicity. Moreover, some structural changes in cardiac and vascular tissues are also patent even before any systemic cardiovascular alterations.

1 August 2012 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
GVGema Vera
Gema Vera
VLVisitación López-Miranda
Visitación López-Miranda
EHEsperanza Herradón
Esperanza Herradón
MMMaría Isabel Martín
María Isabel Martín
Raquel AbaloRaquel Abalo
Raquel Abalo